NET PROFIT (x1000 EUR)
EMPLOYEES
Glucox Biotech AB
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
0
|
0
|
0 |
| Financial expenses |
4
|
0
|
0 |
| Earnings before taxes |
-263
|
-153
|
-127 |
| EBITDA |
-71
|
-66
|
-62 |
| Total assets |
712
|
612
|
268 |
| Current assets |
33
|
36
|
19 |
| Current liabilities |
22
|
22
|
24 |
| Equity capital |
143
|
-156
|
-3 |
| - share capital |
135
|
140
|
140 |
| Employees (average) |
0
|
1
|
1 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
20.1%
|
-25.5%
|
-1.1% |
| Turnover per employee |
0
|
0 | |
| Profit as a percentage of turnover | |||
| Return on assets (ROA) |
-36.4%
|
-25.0%
|
-47.4% |
| Current ratio |
150.0%
|
163.6%
|
79.2% |
| Return on equity (ROE) |
-183.9%
|
98.1%
|
4233.3% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
-1
|
0
|
0 |
| Chg. No. of employees % |
-100%
|
0%
|
0% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.